Collaboration Aims to Strengthen Health Systems and Accelerate Development of Next-Generation Treatments JAKARTA (July 30, 2025)—The Ministry of Health of
Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference.
SEONGNAM-SI, South Korea and NEW YORK, US. Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs
TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the European Regimen Accelerator for Tuberculosis
TB Alliance has built the largest portfolio of potential new tuberculosis (TB) treatments in history. Since inception, it has introduced
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
